Clostridium difficile infection

Current Problems in Surgery

Volumn 50, Issue 7, 2013, Pages 302-337

  Stanley, J D ^a   Bartlett, J G ^a   Dart, B W ^a   Ashcraft, J H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B1 TOXIN; BACTERIAL TOXIN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PROBIOTIC AGENT; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; ACTIVE IMMUNIZATION; AGE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CELL CYTOTOXICITY NEUTRALIZATION ASSAY; CHILD; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON LAVAGE; COLON RESECTION; COLONOSCOPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG USE; ENTERITIS; FECAL TRANSPLANT; FECES ANALYSIS; HAND WASHING; HEALTH PROGRAM; HIGH RISK POPULATION; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEOSTOMY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MALIGNANT NEOPLASTIC DISEASE; MICROBIOLOGY; MOLECULAR PATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT CARE; PERINATAL PERIOD; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR; SIGMOIDOSCOPY; SURGICAL RISK; TRANSPLANTATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; ANION EXCHANGE RESINS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLECTOMY; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; DISEASE OUTBREAKS; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; EUROPE; FECES; HUMANS; ILEOSTOMY; IMMUNOGLOBULINS, INTRAVENOUS; INTESTINAL PSEUDO-OBSTRUCTION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84879818060     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2013.02.004     Document Type: Article

References (247)

1. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978, 298(10):531-534.
2. Hall I.C., O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935, 49(2):390-402.
3. Snyder M.L. Further studies on Bacillus difficilis (Hall and O'Toole). J Infect Dis 1937, 60(2):223-231.
4. Smith L.D.S., King E.O. Occurrence of Clostridium difficile in infections of man. J Bacteriol 1962, 84:65-67.
5. Finney J.M.T. Gastroenterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hosp 1893, 4:53-55.
6. Tedesco F.J., Barton R.W., Alpers D.H. Clindamycin-associated colitis: a prospective study. Ann Intern Med 1974, 81(4):429-433.
7. Browne R.A., Fekety R., Silva J., Boyd D.I., Work C.O., Abrams G.D. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J 1977, 141(4):183-192.
8. Bartlett J., Chang T.W., Onderdonk A.B. Comparison of five regimens for treatment of experimental clindamycin-associated colitis. J Infect Dis 1978, 138:81-86.
9. Taylor N.S., Bartlett J.G. Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis 1979, 1(2):379-385.
10. Chang T.W., Gorbach S.L., Bartlett J.B. Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun 1978, 22(2):418-422.
11. Yolken R.H., Whitcomb L.S., Marien G., et al. Enzyme immunoassay for the detection of Clostridium difficile antigen. J Infect Dis 1981, 144(4):378.
12. Laughon B.E., Viscidi R.P., Gdovin S.L., Yolken R.H., Bartlett J.G. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984, 149(5):781-788.
13. Vital signs: preventing Clostridium difficile infections. Morb Mortal Wkly Rep 2012, 61(9):157-162. (CDC) CfDCaP.
14. Khan M.Y., Hall W.H. Staphylococcal enterocolitis: treatment with oral vancomycin. Ann Intern Med 1966, 65:1-8.
15. Rifkin GD, Silva J., Fekety R. Gastrointestinal and systemic toxicity of fecal extracts from hamsters with clindamycin-induced colitis. Gastroenterology 1978, 74(1):52-57.
16. Bartlett J.G., Onderdonk A.B., Cisneros R.L. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology 1977, 73:772-776.
17. Keighley M.R., Burdon D.W., Arabi Y. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978, 2:1667-1668.
18. Fekety R., Silva J., Kauffman C., Buggy B., Deery H.G. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989, 86(1):15-19.
19. Bartlett J.G. Clostridium difficile: progress and challenges. Ann N Y Acad Sci 2010, 1213:62-69.
20. Jones A.M., Kuijper E.J., Wilcox M.H. Clostridium difficile: a European perspective. J Infect 2013, 66(2):115-128.
21. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353(23):2433-2441.
22. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
23. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clini Infect Dis 2005, 41(9):1254-1260.
24. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364(5):422-431.
25. Cornely O.A., Crook D.W., Esposito R., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12(4):281-289.
26. Bakken J.S., Borody T., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9(12):1044-1049.
27. Planche T., Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards?. J Clin Pathol 2011, 64(1):1-5.
28. Walker A.S., Eyre D.W., Wyllie D.H., et al. Characterisation of Clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med 2012, 9(2):e1001172.
29. Eyre D.W., Golubchik T., Gordon N.C., et al. A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. Br Med J Open 2012, 2:3.
30. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7(7):526-536.
31. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18(2):247-263.
32. Freeman J., Bauer M.P., Baines S.D., et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23(3):529-549.
33. Kuehne S.A., Cartman S.T., Heap J.T., Kelly M.L., Cockayne A., Minton N.P. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467(7316):711-713.
34. Sundriyal A., Roberts A.K., Ling R., McGlashan J., Shone C.C., Acharya K.R. Expression, purification and cell cytotoxicity of actin-modifying binary toxin from Clostridium difficile. Protein Expr Purif 2010, 74(1):42-48.
35. Bacci S., Molbak K., Kjeldsen M.K., Olsen K.E. Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis 2011, 17(6):976-982.
36. Geric B., Carman R.J., Rupnik M., et al. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. J Infect Dis 2006, 193(8):1143-1150.
37. Viscidi R., Willey S., Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981, 81(1):5-9.
38. Rupnik M., Songer J.G. Clostridium difficile its potential as a source of foodborne disease. Adv Food Nutr Res 2010, 60:53-66.
39. Killgore G., Thompson A., Johnson S., et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008, 46(2):431-437.
40. Labbe A.C., Poirier L., Maccannell D., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008, 52(9):3180-3187.
41. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
42. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26(3):273-280.
43. Gerding D.N. Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 2010, 31(suppl 1):S32-S34.
44. Petrella L.A., Sambol S.P., Cheknis A., et al. Decreased cure and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, 55(3):351-357.
45. Janezic S., Ocepek M., Zidaric V., Rupnik M. Clostridium difficile genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. BMC Microbiol 2012, 12:48.
46. Vedantam G., Clark A., Chu M., McQuade R., Mallozzi M., Viswanathan V.K. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012, 3(2):121-134.
47. Koene M.G., Mevius D., Wagenaar J.A., et al. Clostridium difficile in Dutch animals: their presence, characteristics and similarities with human isolates. Clin Microbiol Infect 2012, 18(8):778-784.
48. Mulvey M.R., Boyd D.A., Gravel D., et al. Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerg Infect Dis 2010, 16(4):678-681.
49. Stoesser N., Crook D.W., Fung R., et al. Molecular epidemiology of Clostridium difficile strains in children compared with that of strains circulating in adults with Clostridium difficile-associated infection. J Clin Microbiol 2011, 49(11):3994-3996.
50. Goldenberg S.D., French G.L. Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect 2011, 62(5):355-362.
51. Morgan O.W., Rodrigues B., Elston T., et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PloS One 2008, 3(3):e1812.
52. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992, 15(4):573-581.
53. Fekety R., Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. J Am Med Assoc 1993, 269(1):71-75.
54. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359(18):1932-1940.
55. Shannon-Lowe J., Matheson N.J., Cooke F.J., Aliyu S.H. Prevention and medical management of Clostridium difficile infection. Br Med J 2010, 340:c1296.
56. McFarland L.V., Mulligan M.E., Kwok R.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989, 320(4):204-210.
57. Johnson S., Clabots C.R., Linn F.V., Olson M.M., Peterson L.R., Gerding D.N. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990, 336(8707):97-100.
58. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. HCUP statistical brief no. 124. 2011(HCUP Statistical Brief no. 124). Accessed 2012.
59. VerLee K.E., Finks J.L., Wilkins M.J., Wells E.V. Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002-2008. Public Health Rep 2012, 127(1):62-71.
60. Gouliouris T., Brown N.M., Aliyu S.H. Prevention and treatment of Clostridium difficile infection. Clin Med 2011, 11(1):75-79.
61. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004, 171(5):466-472.
62. Barbut F., Jones G., Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011, 24(4):370-376.
63. Clements A.C., Magalhaes R.J., Tatem A.J., Paterson D.L., Riley T.V. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10(6):395-404.
64. Goorhuis A., Bakker D., Corver J., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47(9):1162-1170.
65. Buffet-Bataillon S., Tattevin P., Senechal H., Cormier M., Vincent P. Clostridium difficile O27 colitis: Hospital-onset but community-acquired. Eur J Clin Microbiol Infect Dis 2012, 31(9):2263-2267.
66. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Baddour L.M. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 2012, 35(5):613-618.
67. Elixhauser A, Jhung M. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005. Healthcare Cost and Utilization Project: Statistical Brief. 〈〉; 2008(50) Accessed 10.11. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.pdf.
68. Stanley J.D., Burns R.P. Clostridium difficile and the surgeon. Am Surg 2010, 76(3):235-244.
69. Kramer A., Schwebke I., Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006, 6:130.
70. Kaatz G.W., Gitlin S.D., Schaberg D.R., et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988, 127(6):1289-1294.
71. Clabots C.R., Johnson S., Olson M.M., Peterson L.R., Gerding D.N. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992, 166(3):561-567.
72. Tabaqchali S., Wilks M. Epidemiological aspects of infections caused by Bacteroides fragilis and Clostridium difficile. Eur J Clin Microbiol Infect Dis 1992, 11(11):1049-1057.
73. Samore M.H., DeGirolami P.C., Tlucko A., Lichtenberg D.A., Melvin Z.A., Karchmer A.W. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994, 18(2):181-187.
74. Brown E., Talbot G.H., Axelrod P., Provencher M., Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990, 11(6):283-290.
75. Gerding D.N., Olson M.M., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986, 146(1):95-100.
76. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40(1):1-15.
77. Hirschhorn L.R., Trnka Y., Onderdonk A., Lee M.L., Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994, 169(1):127-133.
78. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N Engl J Med 1994, 330(4):257-262.
79. Nath S.K., Salama S., Persaud D., et al. Drug risk factors associated with a sustained outbreak of Clostridium difficile diarrhea in a teaching hospital. Can J Infect Dis 1994, 5(6):270-275.
80. Nelson D.E., Auerbach S.B., Baltch A.L., et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994, 15(2):88-94.
81. Talon D., Bailly P., Delmee M., et al. Use of pulsed-field gel electrophoresis for investigation of an outbreak of Clostridium difficile infection among geriatric patients. Eur J Clin Microbiol Infect Dis 1995, 14(11):987-993.
82. Walker K.J., Gilliland S.S., Vance-Bryan K., et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993, 41(9):940-946.
83. Wilcox M.H., Mooney L., Bendall R., Settle C.D., Fawley W.N. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008, 62(2):388-396.
84. Choi H.K., Kim K.H., Lee S.H., Lee S.J. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. J Korean Med Sci 2011, 26(7):859-864.
85. Schalk E., Bohr U.R., Konig B., Scheinpflug K., Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009.
86. Garey K.W., Sethi S., Yadav Y., DuPont H.L. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008, 70(4):298-304.
87. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58(6):403-410.
88. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004, 42(3):1203-1206.
89. Yeom C.H., Cho M.M., Baek S.K., Bae O.S. Risk factors for the development of Clostridium difficile-associated colitis after colorectal cancer surgery. J Korean Soc Coloproctol 2010, 26(5):329-333.
90. Wren S.M., Ahmed N., Jamal A., Safadi B.Y. Preoperative oral antibiotics in colorectal surgery increase the rate of Clostridium difficile colitis. Arch Surg 2005, 140(8):752-756.
91. McFarland L.V., Surawicz C.M., Stamm W.E. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990, 162(3):678-684.
92. Wenisch J.M., Schmid D., Tucek G., et al. A prospective cohort study on hospital mortality due to Clostridium difficile infection. Infection 2012, 40(5):479-484.
93. Tsiouris A., Neale J.A., Reickert C.A., Times M. Clostridium difficile of the ileum following total abdominal colectomy, with or without proctectomy: who is at risk?. Dis Colon Rectum 2012, 55(4):424-428.
94. Zilberberg M.D., Shorr A.F., Micek S.T., Doherty J.A., Kollef M.H. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med 2009, 37(9):2583-2589.
95. Welfare M.R., Lalayiannis L.C., Martin K.E., Corbett S., Marshall B., Sarma J.B. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011, 79(4):359-363.
96. Grundfest-Broniatowski S., Quader M., Alexander F., Walsh R.M., Lavery I., Milsom J. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 1996, 39(6):619-623.
97. Lipsett P.A., Samantaray D.K., Tam M.L., Bartlett J.G., Lillemoe K.D. Pseudomembranous colitis: a surgical disease?. Surgery Sep 1994, 116(3):491-496.
98. Trudel J.L., Deschenes M., Mayrand S., Barkun A.N. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 1995, 38(10):1033-1038.
99. Jobe B.A., Grasley A., Deveney K.E., Deveney C.W., Sheppard B.C. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg 1995, 169(5):480-483.
100. Mistry B., Longo W., Solomon H., Garvin P. Clostridium difficile colitis requiring subtotal colectomy in a renal transplant recipient: a case report and review of literature. Transplant Proc 1998, 30(7):3914.
101. Viswanath Y.K., Griffiths C.D. The role of surgery in pseudomembranous enterocolitis. Postgrad Med J 1998, 74(870):216-219.
102. Synnott K., Mealy K., Merry C., Kyne L., Keane C., Quill R. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 1998, 85(2):229-231.
103. Klipfel A.A., Schein M., Fahoum B., Wise L. Acute abdomen and Clostridium difficile colitis: still a lethal combination. Dig Surg 2000, 17(2):160-163.
104. Villanueva-Saenz E., Herrera J.T., Martinez-Hernandez Magro P., Ruiz-Esparza J.P., Parrado-Montano J.W., Mejia C. Toxic megacolon secondary to pseudomembranous colitis. Rev Gastroenterol Mex 2001, 66(3):141-145.
105. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235(3):363-372.
106. Dobson G., Hickey C., Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med 2003, 29(6):1030.
107. Longo W.E., Mazuski J.E., Virgo K.S., Lee P., Bahadursingh A.N., Johnson F.E. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004, 47(10):1620-1626.
108. Keven K., Basu A., Re L., et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004, 6(1):10-14.
109. Jennings L.J., Hanumadass M. Silver sulfadiazine induced Clostridium difficile toxic megacolon in a burn patient: case report. Burns 1998, 24(7):676-679.
110. Koss K., Clark M.A., Sanders D.S., Morton D., Keighley M.R., Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis 2006, 8(2):149-154.
111. Lamontagne F., Labbe A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007, 245(2):267-272.
112. Greenstein A.J., Byrn J.C., Zhang L.P., Swedish K.A., Jahn A.E., Divino C.M. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery 2008, 143(5):623-629.
113. Berman L., Carling T., Fitzgerald T.N., et al. Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol 2008, 42(5):476-480.
114. Byrn J.C., Maun D.C., Gingold D.S., Baril D.T., Ozao J.J., Divino C.M. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008, 143(2):150-154. [discussion 5].
115. Ali S.O., Welch J.P., Dring R.J. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008, 74(1):20-26.
116. Hall J.F., Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg 2008, 196(3):384-388.
117. Chan S., Kelly M., Helme S., Gossage J., Modarai B., Forshaw M. Outcomes following colectomy for Clostridium difficile colitis. Int J Surg 2009, 7(1):78-81.
118. Sailhamer E.A., Carson K., Chang Y., et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg 2009, 144(5):433-439. [discussion 9-40].
119. Rogers M.A., Greene M.T., Saint S., et al. Higher rates of Clostridium difficile infection among smokers. PloS One 2012, 7(7):e42091.
120. Kent K.C., Rubin M.S., Wroblewski L., Hanff P.A., Silen W. The impact of Clostridium difficile on a surgical service: a prospective study of 374 patients. Ann Surg 1998, 227(2):296-301.
121. Collini P.J., Bauer M., Kuijper E., Dockrell D.H. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect 2012, 64(2):131-147.
122. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
123. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102(9):2047-2056. [quiz 57].
124. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34(11-12):1269-1281.
125. Aslam S., Musher D.M. An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroenterol Clin North Am 2006, 35(2):315-335.
126. Gouraud A., Vochelle V., Descotes J., Vial T. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. Clin Drug Invest 2010, 30(8):559-563.
127. Aseeri M., Schroeder T., Kramer J., Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008, 103(9):2308-2313.
128. Leonard A.D., Ho K.M., Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J 2012, 42(5):591-594.
129. Beaulieu M., Williamson D., Pichette G., Lachaine J. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 2007, 28(11):1305-1307.
130. Mogg G.A., Keighley M.R., Burdon D.W., et al. Antibiotic-associated colitis-a review of 66 cases. Br J Surg 1979, 66(10):738-742.
131. Wistrom J., Norrby S.R., Myhre E.B., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001, 47(1):43-50.
132. Sunenshine R.H., McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 2006, 73(2):187-197.
133. Stevens D.L., Bryant A., Berger A., von Eichel-Streiber C. Clostridium. Manual of Clinical Microbiology 2011, ASM Press, Washington, DC. 10th ed. V. James (Ed.).
134. Reller M.E., Alcabasa R.C., Lema C.A., Carroll K.C. Comparison of two rapid assays for Clostridium difficile common antigen and a C difficile toxin A/B assay with the cell culture neutralization assay. Am J Clin Pathol 2010, 133(1):107-109.
135. Badger V.O., Ledeboer N.A., Graham M.B., Edmiston C.E. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. J Parenter Enteral Nutr 2012, 36(6):645-662.
136. Shetty N., Wren M.W., Coen P.G. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. J Hosp Infect 2011, 77(1):1-6.
137. Barkin J.A., Nandi N., Miller N., Grace A., Barkin J.S., Sussman D.A. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. Dig Dis Sci 2012, 57(10):2592-2599.
138. Efron P.A., Mazuski J.E. Clostridium difficile colitis. Surg Clin North Am 2009, 89(2):483-500. x.
139. Catanzaro M., Cirone J. Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. Am J Infect Control 2012, 40(7):663-666.
140. Carroll K.C. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe 2011, 17(4):170-174.
141. Sharp S.E., Ruden L.O., Pohl J.C., Hatcher P.A., Jayne L.M., Ivie W.M. Evaluation of the C.Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol 2010, 48(6):2082-2086.
142. Fenner L., Widmer A.F., Goy G., Rudin S., Frei R. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008, 46(1):328-330.
143. Ticehurst J.R., Aird D.Z., Dam L.M., Borek A.P., Hargrove J.T., Carroll K.C. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006, 44(3):1145-1149.
144. Larson A.M., Fung A.M., Fang F.C. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol 2010, 48(1):124-130.
145. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008, 46(suppl 1):S12-S18.
146. Burkart N.E., Kwaan M.R., Shepela C., et al. Indications and relative utility of lower endoscopy in the management of Clostridium difficile infection. Gastroenterol Res Pract 2011, 2011:626582.
147. Boland G.W., Lee M.J., Cats A., Mueller P.R. Pseudomembranous colitis: diagnostic sensitivity of the abdominal plain radiograph. Clin Radiol 1994, 49(7):473-475.
148. Perera A.D., Akbari R.P., Cowher M.S., et al. Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. Am Surg 2010, 76(4):418-421.
149. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346(5):334-339.
150. Iacobuzio-Donahue C.A., Montgomery E.A. Gastrointestinal and Liver Pathology 2011, Elsevier/Saunders Publishing, Philadelphia, PA. 2nd ed.
151. Guarner J., Bhatnagar J., Shane A.L., et al. Correlation of the detection of Clostridium difficile toxins in stools and presence of the clostridia in tissues of children. Hum Pathol 2010, 41(11):1586-1592.
152. Johnson S., Gerding D.N., Olson M.M., et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990, 88(2):137-140.
153. Wullt M., Odenholt I., Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect Control Hosp Epidemiol 2003, 24(10):765-768.
154. Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012, 55(suppl 2):S65-S70.
155. Ratnayake L., McEwen J., Henderson N., et al. Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106. J Hosp Infect 2011, 79(3):242-247.
156. Aldeyab M.A., Kearney M.P., Scott M.G., et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012, 67(12):2988-2996.
157. Malkan A.D., Scholand S.J. Preventing downstream Clostridium difficile infections with upstream antibiotic management. Med Hypotheses 2012, 78(1):136-137.
158. Bauer M.P., Kuijper E.J., van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15(12):1067-1079.
159. Bartlett J.G., Chang T.W., Moon N., Onderdonk A.B. Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res 1978, 39(9):1525-1530.
160. Fekety R., Silva J., Toshniwal R., et al. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis 1979, 1(2):386-397.
161. Figueroa I., Johnson S., Sambol S.P., Goldstein E.J., Citron D.M., Gerding D.N. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012, 55(suppl 2):S104-S109.
162. Bartlett J.G. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 2009, 11(1):21-28.
163. Johnson A.P., Wilcox M.H. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 2012, 67(12):2788-2792.
164. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45(3):302-307.
165. Vardakas K.Z., Polyzos K.A., Patouni K., Rafailidis P.I., Samonis G., Falagas M.E. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012, 40(1):1-8.
166. Crook D.W., Walker A.S., Kean Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012, 55(suppl 2):S93-S103.
167. Louie T.J., Cannon K., Byrne B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012, 55(suppl 2):S132-S142.
168. Johnson S., Schriever C., Patel U., Patel T., Hecht D.W., Gerding D.N. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15(6):290-291.
169. Musher D.M., Logan N., Bressler A.M., Johnson D.P., Rossignol J.F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009, 48(4):e41-e46.
170. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007, (3):CD004610.
171. Herpers B.L., Vlaminckx B., Burkhardt O., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009, 48(12):1732-1735.
172. Venugopal A.A., Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012, 55(suppl 2):S71-S76.
173. Taylor N.S., Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980, 141(1):92-97.
174. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342(6):390-397.
175. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011, 60(Pt 8):1070-1079.
176. Drudy D., Calabi E., Kyne L., et al. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 2004, 41(3):237-242.
177. Kyne L., Farrell R.J., Kelly C.P. Clostridium difficile. Gastroenterol Clin North Am 2001, 30(3):753-777. [ix-x].
178. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011, 365(18):1693-1703.
179. Aronsson B., Granstrom M., Mollby R., Nord C.E. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985, 13(3):97-101.
180. Viscidi R., Laughon B.E., Yolken R., et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983, 148(1):93-100.
181. Abougergi M.S., Broor A., Cui W., Jaar B.G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010, 5(1):E1-E9.
182. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010, 362(3):197-205.
183. Foglia G., Shah S., Luxemburger C., Pietrobon P.J. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30(29):4307-4309.
184. Rebeaud F., Bachmann M.F. Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 2012, 11(4):469-479.
185. Na X., Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol 2011, 45(suppl):S154-S158.
186. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Ther Adv Gastroenterol 2011, 4(3):185-197.
187. Pillai A., Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008, (1):CD004611.
188. Johnson S. Meeting the challenge of recurrent Clostridium difficile infection. J Hosp Med 2012, 7(suppl 3):S11-S13.
189. Wenisch C., Parschalk B., Hasenhundl M., Hirschl A.M., Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996, 22(5):813-818.
190. Hu M.Y., Katchar K., Kyne L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009, 136(4):1206-1214.
191. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005, 40(11):1591-1597.
192. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97(7):1769-1775.
193. Cadle R.M., Mansouri M.D., Logan N., Kudva D.R., Musher D.M. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007, 64(22):2359-2363.
194. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994, 271(24):1913-1918.
195. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44(5):854-859.
196. Brandt L.J., Reddy S.S. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011, 45(suppl):S159-S167.
197. Brandt L.J. Fecal microbiota transplantation: patient and physician attitudes. Clin Infect Dis 2012.
198. Nomura K., Fujimoto Y., Yamashita M., et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009, 44(1):74-78.
199. Heard S.R., Wren B., Barnett M.J., Thomas J.M., Tabaqchali S. Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol Infect 1988, 100(1):63-72.
200. Khan A., Raza S., Batul S.A., et al. The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Patents Anti-Infect Drug Disc 2012, 7(2):157-170.
201. Abrahamian F.M., Talan D.A., Moran G.J., Pinner R. Update on emerging infections from the Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. Ann Emerg Med 2006, 48(1):55-59.
202. Hookman P., Barkin J.S. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009, 15(13):1554-1580.
203. Lew M.A., Kehoe K., Ritz J., et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995, 13(1):239-250.
204. Gellad Z.F., Alexander B.D., Liu J.K., et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007, 9(4):276-280.
205. Munoz P., Giannella M., Alcala L., et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?. J Heart Lung Transpl 2007, 26(9):907-914.
206. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5(3):345-351.
207. Nguyen G.C., Kaplan G.G., Harris M.L., Brant S.R. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103(6):1443-1450.
208. Sinh P., Barrett T.A., Yun L. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Pract 2011, 2011:136064.
209. Ricciardi R., Ogilvie J.W., Roberts P.L., Marcello P.W., Concannon T.W., Baxter N.N. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum 2009, 52(1):40-45.
210. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14(10):1432-1442.
211. Nylund C.M., Goudie A., Garza J.M., Fairbrother G., Cohen M.B. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011, 165(5):451-457.
212. Kim J., Smathers S.A., Prasad P., Leckerman K.H., Coffin S., Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008, 122(6):1266-1270.
213. Rutledge-Taylor K., Matlow A., Gravel D., et al. A point prevalence survey of health care-associated infections in Canadian pediatric inpatients. Am J Infect Control 2012, 40(6):491-496.
214. Benson L., Song X., Campos J., Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007, 28(11):1233-1235.
215. Kim J., Shaklee J.F., Smathers S., et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J 2012, 31(2):134-138.
216. Toltzis P., Dul M., O'Riordan M.A., Melnick D., Lo M., Blumer J. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit. Pediatr Crit Care Med 2009, 10(1):49-54.
217. Sandora T.J., Fung M., Flaherty K., et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011, 30(7):580-584.
218. Tai E., Richardson L.C., Townsend J., Howard E., McDonald L.C. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011, 30(7):610-612.
219. Rexach C.E., Tang-Feldman Y.J., Cantrell M.C., Cohen S.H. Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn Microbiol Infect Dis 2006, 56(2):109-114.
220. Hurley B.W., Nguyen C.C. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002, 162(19):2177-2184.
221. Russell G., Kaplan J., Ferraro M., Michelow I.C. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010, 126(1):e239-e242.
222. James A.H., Katz V.L., Dotters D.J., Rogers R.G. Clostridium difficile infection in obstetric and gynecologic patients. South Med J 1997, 90(9):889-892.
223. Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. Morb Mortal Wkly Rep. 2005;54(47):1201-5.
224. Garey K.W., Jiang Z.D., Yadav Y., Mullins B., Wong K., Dupont H.L. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol 2008, 199(4):332-337.
225. Rouphael N.G., O'Donnell J.A., Bhatnagar J., et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol 2008, 198(6). 635 e1-635 e6.
226. Unger J.A., Whimbey E., Gravett M.G., Eschenbach D.A. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol 2011, 2011:267249.
227. Morris J.B., Zollinger R.M., Stellato T.A. Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg 1990, 160(5):535-539.
228. Al-Abed Y.A., Gray E.A., Rothnie N.D. Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. Surgeon 2010, 8(6):330-333.
229. Seder C.W., Villalba M.R., Robbins J., et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 2009, 197(3):302-307.
230. Abou Chakra C.N., Pepin J., Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PloS One 2012, 7(1):e30258.
231. Henrich T.J., Krakower D., Bitton A., Yokoe D.S. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15(3):415-422.
232. Fujitani S., George W.L., Murthy A.R. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32(3):220-228.
233. Rubin M.S., Bodenstein L.E., Kent K.C. Severe Clostridium difficile colitis. Dis Colon Rectum 1995, 38(4):350-354.
234. Redelings M.D., Sorvillo F., Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007, 13(9):1417-1419.
235. Guide to Antimicrobial Chemotherapy. Potoski BA, editor. 4th ed. Pittsburgh, PA: University of Pittsburgh Medical Center; 2008.
236. Belmares J., Gerding D.N., Tillotson G., Johnson S. Measuring the severity of Clostridium difficile infection: implications for management and drug development. Expert Rev Anti-Infect Ther 2008, 6(6):897-908.
237. Belmares J., Gerding D.N., Parada J.P., Miskevics S., Weaver F., Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007, 55(6):495-501.
238. Gujja D., Friedenberg F.K. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009, 29(6):635-642.
239. Louie TGM, Grimard D. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, Abstract K-425a; 2007.
240. Louie T.J., Peppe J., Watt C.K., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006, 43(4):411-420.
241. McEllistrem M.C., Carman R.J., Gerding D.N., Genheimer C.W., Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005, 40(2):265-272.
242. Marx C.E., Morris A., Wilson M.L., Reller L.B. Fecal leukocytes in stool specimens submitted for Clostridium difficile toxin assay. Diagn Microbiol Infect Dis 1993, 16(4):313-315.
243. Medich D.S., Lee K.K., Simmons R.L., Grubbs P.E., Yang H.C., Showalter D.P. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992, 127(7):847-852. [discussion 52-3].
244. Cameron JL, Cameron AM. Current Surgical Therapy. 10th ed., Philadelphia, PA: Elsevier/Mosby, 2011.
245. Oppermann T.E., Christopherson W.A., Stahlfeld K.R. Fulminant Clostridium difficile colitis isolated to the ascending colon by a diverting transverse loop colostomy. Am Surg 2009, 75(9):859-860.
246. Olivas A.D., Umanskiy K., Zuckerbraun B., Alverdy J.C. Avoiding colectomy during surgical management of fulminant Clostridium difficile colitis. Surg Infect 2010, 11(3):299-305.
247. Neal M.D., Alverdy J.C., Hall D.E., Simmons R.L., Zuckerbraun B.S. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011, 254(3):423-427. [discussion 7-9].